002907 华森制药
已收盘 07-03 15:00:00
资讯
新帖
简况
华森制药最新公告:收到化学原料药再注册批准通知书
证券之星 · 06-25
华森制药最新公告:收到化学原料药再注册批准通知书
华森制药(002907.SZ)收到有关铝碳酸镁化学原料药再注册批准通知书
智通财经网 · 06-25
华森制药(002907.SZ)收到有关铝碳酸镁化学原料药再注册批准通知书
华森制药最新公告:公司药品生产许可证变更 核减委托生产
证券之星 · 06-24
华森制药最新公告:公司药品生产许可证变更 核减委托生产
华森制药(002907.SZ):注射用甘草酸二铵完成境内生产药品备案
智通财经 · 06-20
华森制药(002907.SZ):注射用甘草酸二铵完成境内生产药品备案
华森制药:6月18日召开分析师会议,海口复兴城投资(有限合伙)、红思客资产等多家机构参与
证券之星 · 06-18
华森制药:6月18日召开分析师会议,海口复兴城投资(有限合伙)、红思客资产等多家机构参与
华森制药最新公告:近日获得富马酸伏诺拉生片药品注册证书
证券之星 · 06-17
华森制药最新公告:近日获得富马酸伏诺拉生片药品注册证书
华森制药(002907.SZ):富马酸伏诺拉生片(10mg及20mg)获得药品注册证书
智通财经 · 06-17
华森制药(002907.SZ):富马酸伏诺拉生片(10mg及20mg)获得药品注册证书
华森制药(002907.SZ):八味芪龙颗粒获批国家首家中药二级保护品种
智通财经网 · 05-29
华森制药(002907.SZ):八味芪龙颗粒获批国家首家中药二级保护品种
华森制药(002907.SZ)2023年度权益分派:每10股派0.5元
智通财经 · 05-27
华森制药(002907.SZ)2023年度权益分派:每10股派0.5元
华森制药:5月23日进行路演,投资者参与
证券之星 · 05-24
华森制药:5月23日进行路演,投资者参与
华森制药最新公告:药品生产许可证变更
证券之星 · 05-15
华森制药最新公告:药品生产许可证变更
华森制药最新公告:一季度净利润4035.13万元 同比增长34.05%
证券之星 · 04-28
华森制药最新公告:一季度净利润4035.13万元 同比增长34.05%
华森制药(002907.SZ)发一季度业绩,净利润4035.13万元,同比增长34.05%
智通财经 · 04-28
华森制药(002907.SZ)发一季度业绩,净利润4035.13万元,同比增长34.05%
美股减肥药巨头大涨刺激,A股概念股持续火爆,高盛也来点火...
格隆汇 · 03-08
美股减肥药巨头大涨刺激,A股概念股持续火爆,高盛也来点火...
加载更多
公司概况
公司名称:
重庆华森制药股份有限公司
所属行业:
医药制造业
上市日期:
2017-10-20
主营业务:
重庆华森制药股份有限公司主要从事中成药、化学药的研发、生产和销售,拥有片剂、颗粒剂、胶囊剂、软胶囊剂、散剂、粉针剂、冻干粉针剂、原料药、中药提取、小容量注射剂等11条生产线。公司荣获“新中国成立70周年医药行业标杆企业”荣誉称号,2019中国医药工业100强,2018年度中国中药企业TOP100,2018年度中国医药行业成长50强,中华中医药学会科学技术奖一等奖项和荣誉,并在中国非处方药物协会举办的2019年度中国非处方药生产企业排名活动中取得第58位的佳绩。公司获得由国家工业和信息化部评为“2021年国家技术创新示范企业”、由中国合格评定国家认可委员会颁发“中国合格评定国家认可委员会试验室证书”,由中华全国工商联合会、中国人力资源和社会保障部、中华全国总工会评为“全国就业与社会保障先进民营企业”、由重庆市工商业联合会评为“重庆民营企业科技创新指数100强”及“重庆制造业民营企业100强”。
发行价格:
4.53
{"stockData":{"symbol":"002907","market":"SZ","secType":"STK","nameCN":"华森制药","latestPrice":12.48,"timestamp":1719990186000,"preClose":12.78,"halted":0,"volume":2386600,"delay":0,"floatShares":309000000,"shares":418000000,"eps":0.1029,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.3,"latestTime":"07-03 15:00:00","open":12.73,"high":12.82,"low":12.43,"amount":29995000,"amplitude":0.0305,"askPrice":12.49,"askSize":16,"bidPrice":12.48,"bidSize":46,"shortable":0,"etf":0,"ttmEps":0.1029,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1720056600000},"adr":0,"adjPreClose":12.78,"symbolType":"stock","openAndCloseTimeList":[[1719970200000,1719977400000],[1719982800000,1719990000000]],"highLimit":14.06,"lowLimit":11.5,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":417596314,"pbRate":3.22,"roa":"--","roe":"2.46%","epsLYR":0.0783,"committee":0.809442,"marketValue":5212000000,"floatMarketCap":3855000000,"peRate":121.282801,"changeRate":-0.0235,"turnoverRate":0.0077,"status":1},"requestUrl":"/m/hq/s/002907","defaultTab":"news","newsList":[{"id":"2446899063","title":"华森制药最新公告:收到化学原料药再注册批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2446899063","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446899063?lang=zh_cn&edition=full","pubTime":"2024-06-25 16:34","pubTimestamp":1719304456,"startTime":"0","endTime":"0","summary":"华森制药公告,公司近日收到市药监局核准签发的铝碳酸镁《化学原料药再注册批准通知书》。该批准确保了铝碳酸镁的正常生产,保障了原料药质量及供应,并有助于控制生产成本,使产品在集采中更具优势。公司将严格按照要求开展相关工作,持续为市场提供高品质产品。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062500030866.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002907","BK0239"],"gpt_icon":0},{"id":"2446954928","title":"华森制药(002907.SZ)收到有关铝碳酸镁化学原料药再注册批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2446954928","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446954928?lang=zh_cn&edition=full","pubTime":"2024-06-25 16:00","pubTimestamp":1719302435,"startTime":"0","endTime":"0","summary":"智通财经APP讯,华森制药(002907.SZ)发布公告,公司于近日收到重庆市药品监督管理局核准签发的关于公司化学原料药铝碳酸镁的《化学原料药再注册批准通知书》。该原料药用于生产铝碳酸镁咀嚼片。更多港股重磅资讯,下载智通财经app更多港股及海外理财资讯,请点击www.zhitongcaijing.com(搜索“智通财经”);欲加入智通港股投资群,请加智通客服微信(ztcjkf)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1140050.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","002907"],"gpt_icon":0},{"id":"2445028329","title":"华森制药最新公告:公司药品生产许可证变更 核减委托生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2445028329","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445028329?lang=zh_cn&edition=full","pubTime":"2024-06-24 16:52","pubTimestamp":1719219153,"startTime":"0","endTime":"0","summary":"华森制药公告,公司近日收到重庆市药监局颁发的《药品生产许可证》,此次变更主要涉及核减委托生产。此次核减委托生产受托方是成都通德药业有限公司,委托品种是注射用奥美拉唑钠、注射用甲磺酸加贝酯,委托有效期至2025年10月30日。此次核减委托生产表明注射用奥美拉唑钠、注射用甲磺酸加贝酯将由公司自行生产。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062400022210.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002907"],"gpt_icon":0},{"id":"2444678562","title":"华森制药(002907.SZ):注射用甘草酸二铵完成境内生产药品备案","url":"https://stock-news.laohu8.com/highlight/detail?id=2444678562","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444678562?lang=zh_cn&edition=full","pubTime":"2024-06-20 16:38","pubTimestamp":1718872695,"startTime":"0","endTime":"0","summary":"智通财经APP讯,华森制药(002907.SZ)公告,公司于近日从国家药品监督管理局网站查询获知公司产品注射用甘草酸二铵完成了境内生产药品备案(新增生产场地、更新生产企业名称或地址),并于国家药监局网站公示备案信息。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1137931.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","002907"],"gpt_icon":0},{"id":"2444992107","title":"华森制药:6月18日召开分析师会议,海口复兴城投资(有限合伙)、红思客资产等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2444992107","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444992107?lang=zh_cn&edition=full","pubTime":"2024-06-18 18:14","pubTimestamp":1718705646,"startTime":"0","endTime":"0","summary":"证券之星消息,2024年6月18日华森制药发布公告称公司于2024年6月18日召开分析师会议,海口复兴城投资投研总监 游波、红思客资产基金经理 杨岌 研究员 张学聪、泽源私募邓芸 史东涛参与。华森制药2024年一季报显示,公司主营收入2.28亿元,同比上升21.78%;归母净利润4035.13万元,同比上升34.05%;扣非净利润3726.46万元,同比上升30.41%;负债率12.26%,投资收益-37.17万元,财务费用-470.39万元,毛利率60.66%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061800034475.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002907","BK0239"],"gpt_icon":0},{"id":"2444815348","title":"华森制药最新公告:近日获得富马酸伏诺拉生片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2444815348","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444815348?lang=zh_cn&edition=full","pubTime":"2024-06-17 16:20","pubTimestamp":1718612452,"startTime":"0","endTime":"0","summary":"华森制药公告,公司于近日收到国家药品监督管理局核准签发的关于公司产品富马酸伏诺拉生片(10mg及20mg)的《药品注册证书》。富马酸伏诺拉生片作为一种新型抑酸药物,其作用机制通过阻断H+/K+-ATP酶的K+通道,竞争性阻滞K+与该酶的结合,可长时间停留于胃壁细胞,从而快速抑制胃酸的分泌,用于治疗胃酸相关性疾病,包括反流性食管炎(RE)、胃溃疡、十二指肠溃疡等。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061700018319.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002907"],"gpt_icon":0},{"id":"2444158808","title":"华森制药(002907.SZ):富马酸伏诺拉生片(10mg及20mg)获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2444158808","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444158808?lang=zh_cn&edition=full","pubTime":"2024-06-17 15:59","pubTimestamp":1718611140,"startTime":"0","endTime":"0","summary":"智通财经APP讯,华森制药 发布公告,公司于近日收到国家药品监督管理局核准签发的关于公司产品富马酸伏诺拉生片的《药品注册证书》、。该药品是一种钾离子竞争性酸阻滞剂,用于治疗胃酸相关性疾病,包括反流性食管炎、胃溃疡、十二指肠溃疡等,其作用机制通过阻断H+/K+-ATP酶的K+通道,竞争性阻滞K+与该酶的结合,可长时间停留于胃壁细胞,从而快速抑制胃酸的分泌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1136127.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","002907"],"gpt_icon":0},{"id":"2439519428","title":"华森制药(002907.SZ):八味芪龙颗粒获批国家首家中药二级保护品种","url":"https://stock-news.laohu8.com/highlight/detail?id=2439519428","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439519428?lang=zh_cn&edition=full","pubTime":"2024-05-29 16:16","pubTimestamp":1716970595,"startTime":"0","endTime":"0","summary":"本次国家药监局批准公司药品八味芪龙颗粒为首家中药二级保护品种,保护期限自公告日起七年,加强了对该品种的知识产权保护,将有利于继续提升产品的核心竞争力,对公司的生产经营产生积极的影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1127608.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","002907"],"gpt_icon":0},{"id":"2438607807","title":"华森制药(002907.SZ)2023年度权益分派:每10股派0.5元","url":"https://stock-news.laohu8.com/highlight/detail?id=2438607807","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438607807?lang=zh_cn&edition=full","pubTime":"2024-05-27 18:30","pubTimestamp":1716805856,"startTime":"0","endTime":"0","summary":"智通财经APP讯,华森制药(002907.SZ)发布公告,公司2023年年度权益分派方案为:以公司现有总股本为基数,向全体股东每10股派0.5元人民币现金(含税),本次权益分派股权登记日为:2024年6月3日,除权除息日为:2024年6月4日。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1126579.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002907","BK0239"],"gpt_icon":0},{"id":"2437085384","title":"华森制药:5月23日进行路演,投资者参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2437085384","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437085384?lang=zh_cn&edition=full","pubTime":"2024-05-24 17:28","pubTimestamp":1716542937,"startTime":"0","endTime":"0","summary":"证券之星消息,2024年5月24日华森制药发布公告称公司于2024年5月23日进行路演。截至 2023 年年末,公司电商平台销售额已突破 600 万元。华森制药主营业务:公司是一家集药品研发、生产、销售于一体的综合型制药企业,业态覆盖医药工业、医药商业及医药零售。华森制药2024年一季报显示,公司主营收入2.28亿元,同比上升21.78%;归母净利润4035.13万元,同比上升34.05%;扣非净利润3726.46万元,同比上升30.41%;负债率12.26%,投资收益-37.17万元,财务费用-470.39万元,毛利率60.66%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052400034897.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002907"],"gpt_icon":0},{"id":"2435863308","title":"华森制药最新公告:药品生产许可证变更","url":"https://stock-news.laohu8.com/highlight/detail?id=2435863308","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435863308?lang=zh_cn&edition=full","pubTime":"2024-05-15 18:59","pubTimestamp":1715770798,"startTime":"0","endTime":"0","summary":"华森制药公告,公司于近日收到重庆市药品监督管理局颁发的《药品生产许可证》(许可证编号:渝20150018),本次变更主要涉及细化生产地址及生产范围、增加生产场地。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051500031792.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002907","BK0239"],"gpt_icon":0},{"id":"2430442053","title":"华森制药最新公告:一季度净利润4035.13万元 同比增长34.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430442053","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430442053?lang=zh_cn&edition=full","pubTime":"2024-04-28 19:19","pubTimestamp":1714303189,"startTime":"0","endTime":"0","summary":"华森制药公布2024年一季度报告,报告期营业收入2.28亿元,同比增长21.78%;归属于上市公司股东的净利润4035.13万元,同比增长34.05%;归属于上市公司股东的扣除非经常性损益的净利润3726.46万元,同比增长30.41%;基本每股收益0.0966元。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042800007810.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002907"],"gpt_icon":0},{"id":"2430082712","title":"华森制药(002907.SZ)发一季度业绩,净利润4035.13万元,同比增长34.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430082712","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430082712?lang=zh_cn&edition=full","pubTime":"2024-04-28 15:50","pubTimestamp":1714290609,"startTime":"0","endTime":"0","summary":"智通财经APP讯,华森制药(002907.SZ)发布2024年第一季度报告,报告期内公司实现营业收入2.28亿元,同比增长21.78%;归属于上市公司股东的净利润4035.13万元,同比增长34.05%;归属于上市公司股东扣除非经常性损益净利润3726.46万元,同比增长30.41%;基本每股收益0.0966元/股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1113136.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002907"],"gpt_icon":0},{"id":"2417776067","title":"美股减肥药巨头大涨刺激,A股概念股持续火爆,高盛也来点火...","url":"https://stock-news.laohu8.com/highlight/detail?id=2417776067","media":"格隆汇","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2417776067?lang=zh_cn&edition=full","pubTime":"2024-03-08 11:12","pubTimestamp":1709867558,"startTime":"0","endTime":"0","summary":"供不应求","market":"sg","thumbnail":"https://img3.gelonghui.com/30512-ae89b02e-0177-4110-95da-fc4ee514fc80.jpg?guru_height=370&guru_width=660","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/30512-ae89b02e-0177-4110-95da-fc4ee514fc80.jpg?guru_height=370&guru_width=660"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/703805","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["002907","301281","BK0070","BK4127","LU0106831901.USD","BK4533","IE0034235188.USD","BK4588","BK4550","300255","LU1668664300.SGD","BK0239","BK4552","BK4504","GS","IE00BSNM7G36.USD","BK4585","BK0172","301509"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2017-10-20","address":"重庆市荣昌区工业园区","stockEarnings":[{"period":"1week","weight":-0.0318},{"period":"1month","weight":-0.079},{"period":"3month","weight":-0.1198},{"period":"6month","weight":-0.2504},{"period":"1year","weight":-0.1786},{"period":"ytd","weight":-0.1892}],"companyName":"重庆华森制药股份有限公司","boardCode":"AI0027","perCapita":"9496股","boardName":"医药制造业","registeredCapital":"41759万元","compareEarnings":[{"period":"1week","weight":0.0033},{"period":"1month","weight":-0.0312},{"period":"3month","weight":-0.0283},{"period":"6month","weight":0.0182},{"period":"1year","weight":-0.081},{"period":"ytd","weight":0.0025}],"survey":" 重庆华森制药股份有限公司主要从事中成药、化学药的研发、生产和销售,拥有片剂、颗粒剂、胶囊剂、软胶囊剂、散剂、粉针剂、冻干粉针剂、原料药、中药提取、小容量注射剂等11条生产线。公司荣获“新中国成立70周年医药行业标杆企业”荣誉称号,2019中国医药工业100强,2018年度中国中药企业TOP100,2018年度中国医药行业成长50强,中华中医药学会科学技术奖一等奖项和荣誉,并在中国非处方药物协会举办的2019年度中国非处方药生产企业排名活动中取得第58位的佳绩。公司获得由国家工业和信息化部评为“2021年国家技术创新示范企业”、由中国合格评定国家认可委员会颁发“中国合格评定国家认可委员会试验室证书”,由中华全国工商联合会、中国人力资源和社会保障部、中华全国总工会评为“全国就业与社会保障先进民营企业”、由重庆市工商业联合会评为“重庆民营企业科技创新指数100强”及“重庆制造业民营企业100强”。","serverTime":1720041798783,"listedPrice":4.53,"stockholders":"32528人(较上一季度减少1.11%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华森制药(002907)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华森制药(002907)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华森制药,002907,华森制药股票,华森制药股票老虎,华森制药股票老虎国际,华森制药行情,华森制药股票行情,华森制药股价,华森制药股市,华森制药股票价格,华森制药股票交易,华森制药股票购买,华森制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华森制药(002907)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华森制药(002907)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}